LDN 193189 dihydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: LDN 193189 dihydrochloride
• 英文别名: 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline;dihydrochloride
• 化学式: C25H24Cl2N6
• 分子量: 479.4
• InChiKey: CMQXLLAILGGLRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.86
• 重原子数：
  33
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  58.4
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE, AND CELL MASS THEREOF
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP3715450A1

  公开（公告）日：2020-09-30

  The present invention aims to provide a method for efficiently producing a cell mass containing pituitary tissue from pluripotent stem cells. A method for producing a cell mass containing pituitary tissue, including the following steps (1) and (2): (1) a first step of suspension-culturing pluripotent stem cells to form a cell aggregate in the presence of a Wnt signal transduction pathway inhibiting substance, (2) a second step of suspension-culturing the aggregate obtained in the first step in the presence of a BMP signal transduction pathway activating substance and a Sonic hedgehog signal transduction pathway activating substance, thereby obtaining a cell mass comprising pituitary tissue.

  本发明旨在提供一种利用多能干细胞高效生产含有垂体组织的细胞团的方法。一种生产含有垂体组织的细胞团的方法，包括以下步骤（1）和（2）： (1) 第一步，在 Wnt 信号转导通路抑制物质的存在下，悬浮培养多能干细胞以形成细胞团、 (2) 第二步，在 BMP 信号转导通路激活物质和 Sonic hedgehog 信号转导通路激活物质存在的情况下，悬浮培养第一步中获得的聚集体，从而获得包含垂体组织的细胞团。
• CELL AGGREGATION INCLUDING OLFACTORY NEURON OR PRECURSOR CELL THEREOF, AND METHOD FOR PRODUCING SAME
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP3842527A1

  公开（公告）日：2021-06-30

  A method for producing a cell cluster including an olfactory receptor neuron or a precursor cell thereof, comprising the following steps (1) to (3): step (1) of suspension-culturing a pluripotent stem cell in the presence of a Wnt signaling pathway inhibitory substance to form a cell aggregate; step (2) of suspension-culturing the cell aggregate obtained in the step (1) in the presence of a BMP signaling pathway-activating substance; and step (3) of suspension-culturing the cell aggregate obtained in the step (2) to obtain the cell cluster, wherein step (3) comprises at least one step selected from the group consisting of: step (3a) of suspension-culturing in the presence of an FGF signaling pathway-activating substance; step (3b) of suspension-culturing in the presence of a BMP signaling pathway inhibitory substance; and step (3c) of culturing in the presence of an FGF signaling pathway-activating substance and a BMP signaling pathway inhibitory substance.

  一种生产包括嗅觉受体神经元或其前体细胞的细胞团的方法，包括以下步骤(1)至(3)：步骤(1)在Wnt信号通路抑制物质存在下悬浮培养多能干细胞以形成细胞聚集体；步骤(2)在BMP信号通路激活物质存在下悬浮培养步骤(1)中获得的细胞聚集体；以及步骤(3)悬浮培养步骤(2)中获得的细胞聚集体以获得细胞簇，其中步骤(3)包括至少一个选自由以下组成的组的步骤：在 FGF 信号通路激活物质存在下进行悬浮培养的步骤(3a)； 在 BMP 信号通路抑制物质存在下进行悬浮培养的步骤(3b)；以及 在 FGF 信号通路激活物质和 BMP 信号通路抑制物质存在下进行培养的步骤(3c)。
• RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS
  申请人：The United States Of America, As Represented By The Secretary, Department Of Health And Human Services

  公开号：EP4107255A1

  公开（公告）日：2022-12-28
• CELL CLUSTER INCLUDING OLFACTORY NEURON OR PRECURSOR CELL THEREOF, AND METHOD FOR PRODUCING SAME
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20210308188A1

  公开（公告）日：2021-10-07

  A method for producing a cell cluster including an olfactory receptor neuron or a precursor cell thereof, comprising the following steps (1) to (3): step (1) of suspension-culturing a pluripotent stem cell in the presence of a Wnt signaling pathway inhibitory substance to form a cell aggregate; step (2) of suspension-culturing the cell aggregate obtained in the step (1) in the presence of a BMP signaling pathway-activating substance; and step (3) of suspension-culturing the cell aggregate obtained in the step (2) to obtain the cell cluster, wherein step (3) comprises at least one step selected from the group consisting of: step (3a) of suspension-culturing in the presence of an FGF signaling pathway-activating substance; step (3b) of suspension-culturing in the presence of a BMP signaling pathway inhibitory substance; and step (3c) of culturing in the presence of an FGF signaling pathway-activating substance and a BMP signaling pathway inhibitory substance.